Advertisement
Research Article| Volume 29, ISSUE 7, P658-664, April 01, 1991

The effects of physostigmine infusion on patients with panic disorder

DOI:https://doi.org/10.1016/0006-3223(91)90135-9
The effects of physostigmine infusion on patients with panic disorder
Previous ArticleDose-response effects of oral yohimbine in unrestrained primates
Next ArticlePlatelet [3H]-imipramine binding and leukoencephalopathy in geriatric depression
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Nine patients who met both DSM-III and RDC criteria for panic disorder and nine age-matched normal controls received infusions of physostigmine. The patients and normal controls did not differ in either their self-reported or the observer-reported ratings of anxiety, mood, or activation. The two subject groups also did not differ in blood pressure, pulse, or cortisol responses to physostigmine. Physostigmine did not provoke panic attacks in either the control or patients groups.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Beck A.T.
        • Ward C.H.
        • Mendelsohn M.
        • Mock J.
        • Erbaugh J.
        An inventory for measuring depression.
        Arch Gen Psychiatry. 1961; 4: 561-571
        • Bunney Jr., W.E.
        • Hamburg D.A.
        Methods for reliable longitudinal observations of behavior.
        Arch Gen Psychiatry. 1963; 9: 114-128
        • Charney D.
        • Heninger G.
        • Breier A.
        Noradrenergic function in panic anxiety: Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder.
        Arch Gen Psychiatry. 1984; 41: 751-763
        • Charney D.
        • Heninger G.
        • Jatlow P.
        Increased anxiogenic effects of caffeine in panic disorders.
        Arch Gen Psychiatry. 1985; 42: 233-243
        • Cohen L.S.
        • Biederman J.
        Further evidence for an association between affective disorders and anxiety disorders: Review and case reports.
        J Clin Psychiatry. 1988; 49: 313-316
        • Coryell W.
        • Endicott J.
        • Andreasen N.C.
        • et al.
        Depression and panic attacks: The significance of overlap as reflected in follow-up and family study data.
        Am J Psychiatry. 1988; 145: 293-300
        • Curtis G.C.
        • Cameron O.G.
        • Nesse R.M.
        The Dexamethasone Suppression Test in panic disorder and agoraphobia.
        Am J Psychiatry. 1982; 139: 1043-1046
        • Griez E.
        • Lousberg H.
        • van den Hout M.
        • Van der Bolen G.
        CO2 vulnerability in panic disorder.
        Psychiatry Res. 1987; 20: 87-95
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Holsboer F.
        • von Bardeleben U.
        • Buller R.
        • Heuser I.
        • Steiger A.
        Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism, and panic disorder.
        Horm Metab Res. 1987; 16 (suppl): 8088
        • Janowsky D.S.
        • Risch S.C.
        Role of acetylcholine mechanisms in the affective disorders.
        in: Meltzer H.Y. Psychopharmacology: The Third Generation of Progress. Raven, New York1987: 527-533
        • Janowsky D.S.
        • El-Yousef M.K.
        • Davis J.M.
        • Sekerke H.J.
        A cholinergic-adrenergic hypothesis of mania and depression.
        Lancet. 1972; i: 632-636
        • Janowsky D.S.
        • El-Yousef M.K.
        • Davis J.M.
        • Sekerke H.J.
        Parasympathetic suppression of manic symptoms by physostigmine.
        Arch Gen Psychiatry. 1973; 28: 542-547
        • Janowsky D.S.
        • Risch S.C.
        • Huey L.Y.
        • Kennedy B.
        • Ziegler M.
        Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels.
        Am J Psychiatry. 1985; 142: 738-739
        • Lieberman J.A.
        • Renner R.
        • Lesser M.
        • Coccaro E.
        • Borenstein M.
        • Kane J.M.
        Dexamethasone Suppression Tests in patients with panic disorder.
        Am J Psychiatry. 1983; 140: 917-919
        • Margraf J.
        • Ehlers A.
        • Roth W.T.
        Sodium lactate infusions and panic attacks: A review and critique.
        Psychosom Med. 1986; 48: 23-51
        • Merikangas J.
        • Prusoff B.A.
        • Weissman M.M.
        Parental concordance for affective disorders: Psychopathology in offspring.
        J Affective Disord. 1988; 15: 279-290
        • Overall J.E.
        • Gorham D.R.
        The brief psychiatric rating scale.
        Psychol Rep. 1962; 10: 799-812
        • Pitts F.N.
        • McClure J.N.
        Lactate metabolism in anxiety neurosis.
        N Engl J Med. 1967; 277: 1329-1336
        • Rainey J.M.
        • Pohl R.B.
        • Williams M.
        • Knitter E.
        • Freedman R.
        • Ettedgui E.
        A comparison of lactate and isoproterenol anxiety states.
        Psychopathology. 1984; 17: 74-82
        • Rapaport M.H.
        • Risch S.C.
        • Gillin J.C.
        • Golshan S.
        • Janowsky D.S.
        A blunted growth hormone response to peripheral infusion of human growth hormone releasing factor in patients with panic disorder.
        Am J Psychiatry. 1989; 146: 92-95
        • Rapaport M.H.
        • Risch S.C.
        • Golshan S.
        • Gillin J.C.
        Neuroendocrine effects of ovine corticotropin-releasing hormone in panic disorder patients.
        Biol Psychiatry. 1989; 26: 344-348
        • Roy-Byrne P.P.
        • Uhde T.
        • Post R.
        • Gallucci W.
        • Chrousos G.P.
        • Gold P.W.
        The corticotropin-releasing hormone stimulation test in patients with panic disorder.
        Am J Psychiatry. 1986; 143: 896-899
        • Stein M.B.
        • Uhde T.W.
        Panic disorder and major depression: A tale of two syndromes.
        Psychiatr Clin North Am. 1988; 11: 441-461
        • Stein M.B.
        • Uhde T.W.
        Cortisol response to clonidine in panic disorder: Comparison with depressed patients and normal controls.
        J Nerv Ment Dis. 1988; 176: 431-439
        • Uhde T.
        • Vittone B.J.
        • Siever L.J.
        • Kaye W.H.
        • Post R.M.
        Blunted growth hormone response to clonidine in panic disorder patients.
        Biol Psychiatry. 1986; 21: 1081-1085
        • Uhde T.
        • Joffe R.T.
        • Jimerson D.C.
        • Post R.M.
        Normal urinary free cortisol and plasma MHPG in panic disorder: Clinical and theoretical implications.
        Biol Psychiatry. 1988; 23: 575-585
        • Weissman M.M.
        The epidemiology of anxiety disorders: Rates, risks and familial patterns.
        J Psychiatr Res. 1988; 22: 99-114

      Article info

      Publication history

      Received in revised form: October 24, 1990
      Received: May 2, 1990

      Footnotes

      ☆This work was supported in part by NIMH Grants MH 00393(SCR), MH 39173(SCR), 30914(CRC), MH 18399 (training grant), MH 39738(SCG) and S.D.V.A.M.C. Research Service.

      Identification

      DOI: https://doi.org/10.1016/0006-3223(91)90135-9

      Copyright

      © 1991 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX